Q4 2020 BioInvent International AB Earnings Call Transcript
Welcome to the BioInvent Q4 reports 2020. Today I'm pleased to present CEO, Martin Welschof; and CFO, Stefan Ericsson. (Operator Instructions)
Speakers, please begin.
Yes. Thank you very much for the introduction, and welcome, everybody, to our audiocast for the Q4 2020. The next slide, please.
On the next slide, you see our forward-looking statements since we are listed in Stockholm.
And then on slide number three, you will see a very brief snapshot of the company. So just to remind everybody, we are an antibody discovery and target discovery company, and we are focusing clearly on cancer immunotherapy. And there specifically, we are focusing on overcoming tumor resistance.
We have a lead program, BI-1206. This is currently in a Phase I/II clinical trial for non-Hodgkin lymphoma, and also in a Phase I/II trial for solid tumors, and I'll come back to that later in a little bit more detail.
And then, we have two additional programs. So currently, we have four
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |